Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the choroidal neovascularization market right now?

The market size of choroidal neovascularization has experienced robust growth in the past few years. The market, which stood at $3.37 billion in 2024, is projected to expand to $3.61 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this increase during the historical period include the surge in diseases related to inactive lifestyle, growing instances of age-related macular degeneration, and an upswing in retinal illnesses. Additional factors propelling the market growth encompass an aging populace, escalating eye care expenses, and broadening educational programs and screening initiatives.

How fast Is the choroidal neovascularization market expected to grow, and what’s its future value?

The choroidal neovascularization market is predicted to experience robust expansion in the coming years, reaching a value of $5.64 billion by 2029, reflecting a compound annual growth rate (CAGR) of 7.7%. The growth trajectory in the forecast period is driven by factors such as heightened patient awareness, an increasing adoption rate of optical coherence tomography angiography, an escalating demand for minimally invasive procedures, supportive reimbursement policies, and a rising elderly population. Emerging trends predicted for this period encompass the introduction of intravitreal anti-vascular endothelial (VEGF) therapies, innovative genetic treatments, and gene therapy strategies, as well as the integration of telemedicine, the creation of combination therapies, and bespoke treatment approaches.

Get your choroidal neovascularization market report here!

https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

What are the leading drivers of growth in the choroidal neovascularization market?

The choroidal neovascularization (CNV) market is anticipated to expand due to the escalating incidence of age-related macular degeneration (AMD), a vision-threatening condition predominantly found in the elderly. AMD, an eye disorder, progressively affects the macula causing loss of central vision. The growing cases of AMD can be attributed to an aging demographic, longer life spans, lifestyle modifications, hereditary aspects, and increased exposure to environmental threats. CNV plays a significant role in handling AMD patients by aiding the onset of wet AMD, a stage where abnormal blood vessel growth beneath the retina results in vision impairment. This condition necessitates sophisticated treatments like anti-VEGF therapy to regulate CNV and decelerate the progression of AMD, eventually aiding in the preservation of central vision for those affected. The National Institutes of Health, a US government agency, projected in September 2022 that by 2040, AMD cases may surge to 300 million, and by 2050, around 5.4 million Americans might be impacted. Consequently, the surge in AMD instances is bolstering the choroidal neovascularization market’s growth.

What are the key segments defining the choroidal neovascularization market?

The choroidal neovascularization market covered in this report is segmented –

1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

Who are the key players steering the development of the choroidal neovascularization market?

Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

How are evolving market trends shaping choroidal neovascularization Strategies?

Prominent businesses in the choroidal neovascularization market concentrate on the discovery of novel therapies like photodynamic therapy. The goal is to offer precise and effective treatments to eye care professionals which enhances treatment delivery and patient outcomes. Photodynamic therapy (PDT) embodies a medical procedure that utilizes a photosensitizing agent stimulated by light to target and kill abnormal or cancerous cells. Bausch & Lomb, a Canadian healthcare company, and Modulight, a healthcare firm based in Finland, for example, publicized the approval of the ML6710i photodynamic laser by the Food and Drug Administration, an agency based in the United States, in February 2023. This treatment has been approved for use in conjunction with Bausch + Lomb’s VISUDYNE therapy, intended to treat choroidal neovascularization triggered by age-related macular degeneration (AMD). This state-of-the-art, portable ophthalmic laser offers a targeted methodology for treating abnormal eye blood vessels, aiding in halting further disease development and maintaining vision.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142

Which regions are most influential in expanding the choroidal neovascularization market?

North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autologous Cell Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report

Cell and Gene Therapy Manufacturing Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report

Mycoplasma Testing Global Market Report 2025

https://thebusinessresearchcompany.com/report/mycoplasma-testing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: